Pale Body-Like Inclusion Formation and Neurodegeneration following Depletion of 26S Proteasomes in Mouse Brain Neurones are Independent of alpha-Synuclein by Paine, SML et al.
Pale Body-Like Inclusion Formation and
Neurodegeneration following Depletion of 26S
Proteasomes in Mouse Brain Neurones are Independent
of a-Synuclein
Simon M. L. Paine1,2,4, Glenn Anderson2, Karen Bedford3, Karen Lawler4, R. John Mayer4, James Lowe5,
Lynn Bedford4*
1Neural Development Unit, University College London Institute of Child Health, London, United Kingdom, 2Department of Histopathology, Great Ormond Street Hospital
for Children NHS Trust, London, United Kingdom, 3Hull and East Yorkshire Hospitals, Hull Royal Infirmary, Hull, United Kingdom, 4 School of Biomedical Sciences,
University of Nottingham, Nottingham, United Kingdom, 5Division of Histopathology, School of Molecular Medical Sciences, University of Nottingham, Nottingham,
United Kingdom
Abstract
Parkinson’s disease (PD) is characterized by the progressive degeneration of substantia nigra pars compacta (SNpc)
dopaminergic neurones and the formation of Lewy bodies (LB) in a proportion of the remaining neurones. a-synuclein is the
main component of LB, but the pathological mechanisms that lead to neurodegeneration associated with LB formation
remain unclear. Three pivotal elements have emerged in the development of PD: a-synuclein, mitochondria and protein
degradation systems. We previously reported a unique model, created by conditional genetic depletion of 26S proteasomes
in the SNpc of mice, which mechanistically links these three elements with the neuropathology of PD: progressive
neurodegeneration and intraneuronal inclusion formation. Using this model, we tested the hypothesis that a-synuclein was
essential for the formation of inclusions and neurodegeneration caused by 26S proteasomal depletion. We found that both
of these processes were independent of a-synuclein. This provides an important insight into the relationship between the
proteasome, a-synuclein, inclusion formation and neurodegeneration. We also show that the autophagy-lysosomal pathway
is not activated in 26S proteasome-depleted neurones. This leads us to suggest that the paranuclear accumulation of
mitochondria in inclusions in our model may reflect a role for the ubiquitin proteasome system in mitochondrial
homeostasis and that neurodegeneration may be mediated through mitochondrial factors linked to inclusion biogenesis.
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Introduction
Parkinson’s disease (PD) is defined pathologically by the loss of
dopaminergic (DA) neurones from the substantia nigra pars
compacta (SNpc) and the accumulation of aggregated a-synuclein
in Lewy bodies (LB) in a proportion of the remaining neurones.
Attention is increasingly turning to the concept of proteostasis in
diseases in which abnormal protein accumulation develops in
association with the formation of inclusion bodies [1]. The
formation of inclusions is likely to be cytoprotective [2], with
neuronal death being the result of failure to compensate.
Therefore, it is important to understand which cellular systems
are involved in the formation of inclusion bodies and what leads to
neuronal death in this context. Three elements are regarded as
pivotal in the pathogenesis of neurodegeneration in PD: a-
synuclein, mitochondria and protein degradation systems.
As well as being the defining protein component of LB [3], point
mutations and multiplication of the Snca locus, encoding a-
synuclein, lead to familial forms of the disease, and Snca variation is
associated with an increased risk of developing sporadic PD [4,5].
LB are a feature of these forms of PD and are present in a wide
range of neuronal populations beyond the mesencephalon. Their
presence in the neocortex and limbic system is seen in the second
most common form of dementia, dementia with Lewy bodies
(DLB) [6,7]. LB pathology often coexists with other neurodegen-
erative disorders, such as Alzheimer’s disease (AD) [8]. Despite 15
years of intense study since Snca was first linked to PD [3], the
pathological mechanisms that lead to neurodegeneration associ-
ated with LB formation remain unclear.
Extensive data implicates mitochondrial factors in neurodegen-
eration [9,10]. In addition to several genetic factors known to
cause familial PD linking to mitochondria (e.g. Parkin), respiratory
chain defects in the SN, and other tissues, from sporadic PD cases
have long been recognized and neurotoxins that act via various
mechanisms to impair mitochondrial complex I have been used to
model the disease [9–11]. Mitochondria are a prominent
component of pale bodies (PB), the precursor of LB [12,13].
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Ubiquitin is key to the two main cellular degradation systems:
the ubiquitin proteasome system (UPS) and the autophagy-
lysosomal pathway (ALP) [14]. Ubiquitin-positive inclusions are
a consistent feature of the majority of human neurodegenerative
diseases, suggesting involvement of protein degradation systems
[15–17]. The UPS and ALP have specific roles in the
degradation of a-synuclein in vivo; under normal conditions the
UPS is the main degradation system for a-synuclein whilst the
ALP is recruited with raised a-synuclein levels [18]. Also
relevant is that the formation of LB has been regarded as an
aggresomal process, involving components of the UPS as well as
the ALP [19,20].
Recent attention has focused on the importance of protein
degradation systems in relation to mitochondrial function [21].
The UPS has a role in mitochondrial protein quality control
[22,23], and specifically, mitophagy (the selective degradation of
dysfunctional mitochondria by autophagy). Aberrant mitochon-
dria are selected for mitophagy by PINK1-dependent recruitment
of cytosolic Parkin, an E3 ubiquitin ligase implicated in PD, which
mediates K48- and K63-linked polyubiquitination associated with
the UPS and ALP respectively [24,25]. There is, therefore, a clear
point of convergence between two elements known to be
important in PD pathogenesis: mitochondria and protein degra-
dation systems. Interestingly, a-synuclein has also recently been
found to be directly involved in mitochondrial homeostasis [26–
28].
We previously reported that 26S proteasomal depletion in
mouse brain neurones, including SNpc DA neurones, causes
neurodegeneration and the formation of Lewy-like inclusions
resembling human PB [13]. The mouse inclusions are defined as
PB-like because they are morphologically, neuropathologically and
ultrastructurally similar to PB found in human disease, the
precursor of LB. They contain endogenously formed fibrillar a-
synuclein, ubiquitin, membranous material in vesicles and
mitochondria. Although still a model system, it is important to
emphasize that this is an in vivo mammalian model that brings
together several of the pivotal elements implicated in sporadic PD,
namely: a defect in the UPS, a-synuclein aggregation and
mitochondria. Therefore, this is a model in which to explore
fundamental biological connections between these elements in the
context of inclusion formation and neuronal death.
Using this model, we tested the hypothesis that a-synuclein is
essential for the neurodegeneration and PB-like inclusion forma-
tion that characterize PD. We show here that the ability of 26S
proteasomal impairment to cause neuronal death and inclusion
formation in the SNpc is not moderated by the absence of a-
synuclein. Significantly, this was not a specific response limited to
mesencephelic DA cells; a-synuclein does not modify processes
leading to cortical PB-like inclusions. We also demonstrate that the
ALP is not activated in 26S proteasome-depleted mouse brain
neurones.
Materials and Methods
Ethics Statement
All procedures were carried out under personal and project
licenses granted by the UK Home Office in accordance with the
Animals (Scientific Procedures) Act 1986 and with ethical approval
from the University of Nottingham Ethical Review Committee.
Animal welfare was ensured and no steps were necessary to
ameliorate suffering. Animals were perfusion-fixed or sacrificed
using an approved S1 method.
Animals
Mice lacking the first two exons and upstream untranslated
region of the a-synuclein gene (Snca), encoding amino acids 1–41
of a-synuclein, were kindly provided by Prof. Vladimir Buchman,
University of Cardiff, Wales UK [29]. These mice (Snca 2/2) were
crossed with floxed Psmc1 mice (Psmc1fl/fl) expressing Cre
recombinase from the tyrosine hydroxylase (TH) promoter (THCre)
to achieve catecholaminergic neurone-specific inactivation of
Psmc1 (Psmc1fl/fl;THCre) [13]. TH is expressed from mid-gestation
in midbrain dopaminergic neurones [30]. For forebrain neurone-
specific inactivation of Psmc1, Cre recombinase was expressed
under the control of the calcium calmodulin-dependent protein
kinase IIa promoter (Psmc1fl/fl;CaMKIIa-Cre) [13]. CaMKIIa is
expressed in post-mitotic neurones from approximately post-natal
week 2 [31,32]. All mice were male. Appropriate littermate mice
were used as controls.
Genotyping
Genomic DNA was used in a polymerase chain reaction, 62uC
annealing. Primers: Cre (sense) GGTAGCACCGCAGGTGTAG;
Cre (antisense) CTAATCGCCATCTTCCAGCAG; Psmc1 (wild-
type and floxed sense) TACGAACCTCCTGTCCCAAC; Psmc1
(knock-out sense) CAGAAATACAGCCAGTGACC; Psmc1 (com-
mon antisense) CTGGAACTCAGTGGATTGAG; Snca (com-
mon sense) CAGCTCAAGTTCAGCCACGA; Snca (wild-type
antisense) AAGGAAAGCCGAGTGATGTAC; Snca (knock-out
antisense) ATGGAAGGATTGGAGCTACG.
Histology
For light microscopy, mice were perfused with 0.9% saline
followed by 4% paraformaldehyde (PFA) in phosphate buffered
saline pH 7.4. PFA-fixed brains were processed to paraffin with
chloroform as the clearing agent. General morphological exam-
ination used haematoxylin and eosin staining. Immunostaining
was performed as directed in Vector Laboratories M.O.M
Immunodetection or Vectastain Elite Rabbit IgG ABC kits.
Antigen retrieval used 0.01 M citrate buffer containing 0.05%
Tween-20 pH 6. Primary antibody incubation was for 1 hour at
room temperature [tyrosine hydroxylase (Sigma), a-synuclein (BD
Biosciences), p62 (Enzo Life Sciences), ubiquitin K63-isopeptide
motif (Enzo Life Sciences), lysine 48-linkage specific polyubiquitin
(Millipore), in-house ubiquitin, COX IV (Cell Signalling), cyto-
chrome C (Santa Cruz), LC3B (Sigma) and Cathepsin D (Cell
Signaling and Abcam)]. Double immunofluorescent staining used
similar methods; primary (from different species) and appropriate
fluorescent secondary antibodies were incubated in sequence. For
electron microscopy, mice were perfused with 0.9% saline
followed by gluteraldehyde fixative suitable for EM.
Stereology
Horizontal sections were cut at 7 micrometres. Two consecutive
sections were collected onto a single APES-coated slide starting
rostral to the substantia nigra and continuing through to the
brainstem. Every seventh slide through the SNpc was stained for
TH and counterstained with haematoxylin [33]. The slides were
scanned and analysed with ImageJ. The SNpc was delineated
using anatomical landmarks and neuronal cytology. Neurones
were counted if they fell within the outline of the SNpc, possessed
the characteristic cytological features of a neurone within the
SNpc, had clear cytoplasmic TH immunoreactivity and the
dominant nucleolus was present only in the reference (lower)
section. The count was repeated three times in each of three
animals for each genotype. The sum of the neurones counted for
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each SNpc was divided by the sampling interval in order to
produce an estimate of the total number of neurones for each
animal. The same stereological methods, using haematoxylin and
eosin stained sections, were applied to estimate the total number of
intraneuronal inclusions within the SNpc of the same animals.
Estimation of reference volume used Cavalieri. Statistical signif-
icance was assessed using analysis of variance (ANOVA) and
Tukey HSD post hoc testing.
Western Blotting
Tissue was homogenized in cold lysis buffer [50 mM Tris-HCl
pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100; 0.1%
SDS, 0.5% sodium deoxycholate, protease inhibitors], incubated
on ice for 30 minutes, centrifuged at 160006g to eliminate cellular
debris and protein quantified using the Bradford assay. Proteins
were separated by SDS-PAGE and transferred to nitrocellulose
membrane. Blocking used 5% Marvel in tris buffered saline-0.1%
Tween-20. Incubation in primary [1:2000 LC3B (Sigma); 1:1000
Cathepsin D (Cell Signaling and Abcam) and b-actin (Sigma)] and
appropriate horseradish peroxidise-conjugated secondary antibod-
ies (Sigma) was for 1 hour, room temperature. Proteins were
visualized with ECL substrate (Pierce). Quantity One 1-D analysis
Software was used to calculate band intensity.
Results
a-synuclein Aggregation does not Modify
Neurodegeneration and is not Essential for the
Biogenesis of PB-like Inclusions in 26S Proteasome-
depleted Neurones
We previously demonstrated impaired 26S proteasome function
in mouse neurones, including SNpc DA neurones, caused
neurodegeneration and the formation of intraneuronal PB-like
inclusions [13]. Specifically 26S proteasomal dysfunction was
achieved by Cre/loxP conditional genetic targeting of Psmc1, a key
ATPase subunit of the 19S regulatory particle of the 26S
proteasome. We showed PSMC1 was responsible for the assembly
and activation of the 26S proteasome in mouse neurones in vivo;
the 20S proteolytic core particle and therefore ubiquitin-indepen-
dent proteasomal degradation was not affected [13]. To study
whether a-synuclein directly contributes to the formation of
inclusions and degeneration of DA neurones in the mouse SNpc,
we generated mice constitutively lacking a-synuclein (Snca2/2) and
in which the 26S proteasome was impaired in TH-positive
neurones (Psmc1fl/fl;THCre).
Immunostaining of the mouse SNpc showed a severe loss of
TH-positive neurones in Psmc1fl/fl;THCre mice (Figure 1A). Our
original publication of this model demonstrates that this is
neurodegeneration and not decreased TH expression by TH
and Nissl staining of adjacent sections from the SNpc. We show
results from 3-week-old mice because autonomic dysfunction, as a
consequence of 26S proteasomal depletion in all catecholaminer-
gic (TH) neurones, causes premature death [13]. We recognize
that these are young mice, but emphasize that the neuropathology
following 26S proteasomal dysfunction in SNpc neurones involves
elements pivotal to PD pathways and therefore, this is an
important in vivo model.
Quantification of the total number of TH-positive neurones
showed that the 26S proteasome-depleted mice (Psmc1fl/fl;THCre)
possessed approximately 85% fewer neurones when compared
with control mice (Psmc1fl/fl;THWt), irrespective of the presence
(Snca+/+) or absence (Snca2/2) of a-synuclein (Figure 1B). In
keeping with the analysis of TH-positive neurone number, there
was a significant reduction in the volume of the SNpc when either
group of control mice (Psmc1fl/fl;THWt) was compared with either
group of 26S proteasome-depleted mice (Psmc1fl/fl;THCre)
(Figure 1C). That is, the absence of a-synuclein (Snca2/2) had
no significant effect on the volume of the SNpc.
We previously demonstrated the formation of intraneuronal
eosinophilic PB-like inclusions following 26S proteasomal deple-
tion in surviving mouse SNpc neurones (Psmc1fl/fl;THCre;Snca+/+),
exhibiting a-synuclein, ubiquitin, p62 and cytochrome oxidase IV
(COX IV) immunoreactivity (Figure 2Ai,iii,v,vii,ix,xi) [13]. Care-
ful morphological and immunophenotypical examination re-
vealed, with the exception of a-synuclein (Fig. 2Aiv), that the
inclusions in SNpc neurones lacking a-synuclein (Psmc1fl/
fl;THCre;Snca2/2) were similarly eosinophilic and immunoreactive
to p62, ubiquitin and COX IV (Figure 2Aii,vi,viii,x,xii). We sought
to quantify whether the number of PB-like inclusions in TH-
positive neurones resulting from loss of 26S proteasomes was
modified by a-synuclein. The total number of eosinophilic
inclusions in the SNpc was counted and divided by the total
number of neurones present in this region with the potential to
form inclusions, i.e. TH-positive neurones. Figure 2B shows that
the proportion of neurones bearing inclusions was similar in both
groups of 26S proteasome-depleted mice, irrespective of the
presence (Psmc1fl/fl;THCre;Snca+/+) or absence (Psmc1fl/
fl;THCre;Snca2/2) of a-synuclein.
In order to assess whether this was a specific response of
mesencephelic DA cells, we conditionally deleted Psmc1 in mouse
forebrain neurones by expressing Cre recombinase from the
calcium calmodulin-dependent protein kinase IIa promoter (CaMKIIa-Cre),
causing PB-like inclusions in cortical neurones (Psmc1fl/fl;CaMKIIa-
Cre) [13]. Significantly, we found here too the absence of a-
synuclein (Snca2/2) does not modify the processes leading to
cortical PB-like inclusion formation (Figure 2C). Intranuclear
inclusions were not identified in any of the mice.
Accumulation of Aberrant Mitochondria
We used ultrastructural analysis to investigate more subtle
pathological differences between PB-like inclusions in 26S
proteasome-depleted mice with (Psmc1fl/fl;THCre;Snca+/+) and
without (Psmc1fl/fl;THCre;Snca2/2) a-synuclein. This revealed that
the intraneuronal inclusions in SNpc neurones were indistinguish-
able (Figure 3). The inclusions were composed predominantly of
morphologically abnormal mitochondria, which, in general, had
disrupted or disintegrated cristae (Figures 3D–G). The mitochon-
dria within the inclusions were interspersed with membrane in
numerous small vesicles and granular material (Figures 3E and
3F). We observed the presence of occasional autophagosome-like
structures containing electron-dense material (Figure 3I) as well as
recognizable cytoplasmic elements, including mitochondria
(Figure 3H), but the majority of the vesicles were empty.
The ALP is not Activated in 26S Proteasome-depleted
Neurones
Several studies have shown compensatory activation of the ALP
with proteasome inhibition [18,34,35]. To investigate the involve-
ment of the ALP following 26S proteasomal depletion in our
model and whether this was associated with the membranous
vesicles seen in inclusions, we carried out LC3 and cathepsin D
immunostaining and Western blotting. LC3 is a marker of
autophagosomes and post-translational modification of cytosolic
LC3-I to LC3-II that is associated with autophagosomal mem-
branes is an index of autophagy activation [36,37]. Punctate
endogenous LC3 immunostaining has also been associated with
LC3-II and activation of autophagy with proteasome inhibition
[35]. Overall, we did not consistently detect LC3-positive
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inclusions or the formation of LC3 puncta in 26S proteasome-
depleted neurones, irrespective of the presence or absence of a-
synuclein (Figures 4A and 4B). Further, LC3-cytochrome C
double-immunofluorescent staining did not demonstrate co-
localization of LC3 and mitochondria in inclusions following
26S proteasomal depletion, but LC3 staining was intermixed with
dispersed mitochondria in both 26S proteasome-depleted and
control neurones (Figure S1A). We report that variable LC3
staining was evident in some inclusion bodies and is shown in
Figure S1B. Interestingly, a recent study of Parkin-mediated
mitophagy showed LC3 was associated with dispersed mitochon-
dria, but absent from paranuclear mitochondrial aggregates, and
that 26S proteasome function may facilitate their dispersal and
uptake by the autophagic machinery [38].
To further evaluate the activation of autophagy, we measured
the levels of LC3-II (ratio with b-actin) following Western blotting.
Due to the small size and accuracy of reproducibly dissecting
specifically the mouse SNpc, we used cortical tissue from control
(Psmc1fl/fl;CaMKIIa-Wt) and 26S proteasome-depleted mice
(Psmc1fl/fl;CaMKIIa-Cre). Supporting our immunohistochemical
observations, the levels of LC3-II were not significantly different
between 26S proteasome-depleted and control mice (Figure 4C).
The levels of p62, a substrate of macroautophagy [39], were also
similar (data not shown). However, the presence of p62 in
inclusion bodies in 26S proteasome-depleted neurones is consistent
with previous studies demonstrating it is required for aggregation
of polyubiquitinated proteins and mitochondria [40,41].
Following 26S proteasomal dysfunction we did not identify any
inclusions in the SNpc or cortex that immunostained for cathepsin
D, an essential lysosomal protease (Figures 5A and 5B). These
observations are analogous to an in vitro study in cortical neurones
modeling proteasomal dysfunction by applying pharmacological
inhibitors that showed globular cathepsin D staining with
activation of the ALP, but this was associated with dissolution of
inclusions and did not co-localize with inclusion bodies [34].
Western blot and densitometric analysis showed the levels of
mature cathepsin D were not significantly different between 26S
proteasome-depleted and control mice (Figure 5C). Taken
together, these results suggest that the ALP is not activated in
26S proteasome-depleted neurones.
Discussion
In the present study we have investigated an in vivo model
system of neurodegeneration and inclusion formation that brings
together several of the pivotal elements implicated in PD. We
Figure 1. Neurodegeneration of 26S proteasome-depleted SNpc neurones is not modified by the absence of a-synuclein. (A) TH-
immunoreactive neurones at the level of the SNpc. 56. (B) The total number of TH-positive neurones within the SNpc. n = 3, P,0.01 (ANOVA, Tukey
HSD post hoc test). (C) Volume of the SNpc containing TH-positive neurones. n = 3, P,0.01 (ANOVA, Tukey HSD post hoc test). Control (Psmc1fl/
fl;THWt) vs. 26S proteasome-depleted (Psmc1fl/fl;THCre); presence (Snca+/+) vs. absence (Snca 2/2) of a-synuclein. Error bars indicate SEM.
doi:10.1371/journal.pone.0054711.g001
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have shown that a-synuclein is not essential for the biogenesis of
PB-like inclusions and that it does not modify the neurodegen-
eration that follows in vivo depletion of 26S proteasomes in DA
and cortical neurones. Additionally, we have shown that 26S
proteasomal dysfunction does not lead to activation of the ALP.
In synucleinopathies such as PD and DLB, extensive research
has focused on the over-expression of a-synuclein and its ability to
aggregate [4,5,42]. Many transgenic mice have been created to
over-express human PD variants of a-synuclein, but these models
have not shown region-specific neuronal loss in the pattern seen in
PD [4,42–44]. The relevance of the 26S proteasomal depletion
Figure 2. The absence of a-synuclein does not modify PB-like inclusion biogenesis or morphology following 26S proteasomal
depletion in mouse brain neurones. (A and C) Representative inclusions (arrows) in neurones of the SNpc (Psmc1fl/fl;THCre, A) and cortex (Psmc1fl/
fl;CaMKIIa-Cre, C) in the presence (Snca+/+) and absence (Snca 2/2) of a-synuclein; from the top: hematoxylin and eosin staining, a-synuclein, p62, K48-
and K63-specific polyubiquitin, and COX IV. 636. (B) Absence of a-synuclein (Snca2/2) has no effect on the proportion of TH-positive neurones
bearing eosinophilic inclusions in the 26S proteasome-depleted (Psmc1fl/fl;THCre) SNpc. n = 3, no significant difference (ANOVA). Error bars indicate
SEM.
doi:10.1371/journal.pone.0054711.g002
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Figure 3. The absence of a-synuclein does not modify the ultrastructure of PB-like inclusions in mouse SNpc neurones.
Representative electron micrographs of control (A; Psmc1fl/fl;THWt) and 26S proteasome-depleted SNpc neurones with (B; Psmc1fl/fl;THCre;Snca+/+) and
without (C; Psmc1fl/fl;THCre;Snca2/2) a-synuclein. Enlarged views of the boxed areas are shown in D-F respectively. The inclusions contain mainly
abnormal mitochondria (E-G; m) interspersed with numerous small vesicles (E and F; v). Autophagosome-like structures containing electron-dense
material (E, F and I; arrows) as well as recognizable cytosolic elements including mitochondria (H) are present. n, nucleus; i, PB-like inclusion; m,
mitochondria; v, vesicle and er, endoplasmic reticulum. Scale bar, 500 nm. Psmc1fl/fl;THCre;Snca+/+ (G and H); Psmc1fl/fl;THCre;Snca2/2 (I).
doi:10.1371/journal.pone.0054711.g003
Figure 4. Autophagy is not activated in 26S proteasome-depleted mouse neurones. (A) Absence of LC3 immunoreactivity in
representative neurones of the SNpc (Psmc1fl/fl;THCre, nigral) and cortex (Psmc1fl/fl;CaMKIIa-Cre, cortical) in the presence (Snca+/+) and absence (Snca2/
2) of a-synuclein. The arrows indicate PB-like inclusions. Scale bar, 10 mm. (B) The normal pattern of LC3 in nigral and cortical neurones shows a fine
punctate cytoplasmic staining. Neurones from Psmc1fl/fl;THWt;Snca+/+ (nigral) and Psmc1fl/fl;CaMKIIa-Wt;Snca+/+ (cortical) mice are shown, but the
pattern of LC3 immunostaining was similar in the absence of a-synuclein. Scale bar, 10 mm. (C) Representative Western blot of LC3-I and LC3-II in total
cortical homogenates from control (Psmc1fl/fl;CaMKIIa-Wt) and 26S proteasome-depleted (Psmc1fl/fl;CaMKIIa-Cre) mice. Graph depicts LC3-II levels
normalized to b-actin. n = 4, no significant difference. Error bars indicate SEM.
doi:10.1371/journal.pone.0054711.g004
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model to PD is still under debate because of conflicting data using
20S proteasomal inhibitors in vivo [45–50]. One of the strengths of
our model system is that reproducible depletion of 26S protea-
somes in mesencephelic DA neurones and non-catecholaminergic
cortical neurones is achieved using conditional gene deletion, not
the work of an inhibitor, which may have other effects [51].
However, we recognize that while the inclusions that form in 26S
proteasome-depleted neurones have the characteristics of PB, we
do not know if these would develop into LB if the neurones
survived. Importantly, our work adds to the data on the
pathological significance of the aggregated a-synuclein in neuro-
degeneration using a model in which a-synuclein itself is not over-
expressed. We show that the 26S proteasomal depletion mouse
model does not require a-synuclein aggregation for the manifes-
tations of neurodegeneration.
In vitro and in vivo studies indicate that the proteasome is
important for the degradation of a-synuclein, suggesting alter-
ations in this pathway that lead to the abnormal expression or
distribution of a-synuclein may contribute to a-synuclein neuro-
pathology. In general, these studies have used pharmacological
manipulation of the 20S proteasome that does not differentiate
between ubiquitin-dependent and ubiquitin-independent degra-
dation of the 26S and 20S proteasomes respectively [18,52–54].
The 26S proteasome is a multi-protein complex composed of the
20S proteasome directly abutted by 19S regulatory particles [55–
58]. Our model of 26S proteasomal depletion targets the 19S
regulatory particle and does not affect 20S proteasome function,
providing direct evidence that the 26S proteasome plays a role in
a-synuclein degradation [13]. However, the present data suggests
that 26S proteasomal depletion does not lead to pathological
aggregation of a-synuclein. Since an early study showed ubiquitin-
independent degradation of unmodified a-synuclein by purified
20S proteasomes in vitro [59], it is possible that the 20S proteasome
plays a further role in a-synuclein degradation that would not be
evident in our model and may be of pathological significance.
The relationship between a-synuclein and the proteasome is not
straightforward. It has also been shown that aggregates of a-
synuclein can impair 26S proteasome function, albeit at high
concentrations [13,18,60–66]. It is conflicting, however, if a-
synuclein can impair proteasome function, the absence of a-
synuclein does not lead to less neurodegeneration in this study.
Few studies have investigated proteasomal dysfunction by a-
synuclein in vivo [18,65] and our study suggests that the level of
endogenous a-synuclein following 26S proteasomal depletion may
not be sufficient itself to impair proteasome function.
Although a-synuclein is the gene arguably most closely linked to
PD, multiple disease loci have been identified with relevance for
familial and sporadic disease [67]. How each of these may lead to
a-synuclein aggregation in LB is uncertain. Also, LB are present in
other synucleinopathies as well as other neurodegenerative
diseases, where, in general, a-synuclein is not known to be a
primary causative factor, and a proportion of clinically normal
people have LB, although this may be sub-threshold pathology [6–
8,68–70].
Our data provides evidence that the neurodegenerative
processes that are initiated by, or lead to, proteasomal impairment
may lead to the formation of a-synuclein inclusions. The
paranuclear location of a-synuclein aggregation may be occurring
Figure 5. The lysosomal pathway is not activated in 26S proteasome-depleted neurones. (A) Representative immunostaining for
cathepsin D in neurones of the SNpc (Psmc1fl/fl;THCre, nigral) and cortex (Psmc1fl/fl;CaMKIIa-Cre, cortical) in the presence (Snca+/+) and absence (Snca2/
2) of a-synuclein. Scale bar, 10 mm. The arrows indicate PB-like inclusions. (B) The normal pattern of cathepsin D in nigral and cortical neurones shows
a fine punctate cytoplasmic staining. Neurones from Psmc1fl/fl;THWt;Snca+/+ (nigral) and Psmc1fl/fl;CaMKIIa-Wt;Snca+/+ (cortical) mice are shown, but
cathepsin D staining was similar in the absence of a-synuclein. Scale bar, 10 mm. (C) Representative Western blot and densitometric analysis of mature
cathepsin D in total cortical homogenates from control (Psmc1fl/fl;CaMKIIa-Wt) and 26S proteasome-depleted (Psmc1fl/fl;CaMKIIa-Cre) mice. Graph
depicts mature cathepsin D levels normalized to b-actin. n = 4, no significant difference. Error bars indicate SEM.
doi:10.1371/journal.pone.0054711.g005
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as the consequence of activation of a cytoprotective pathway, e.g.
an aggresome-like mechanism following proteasomal inhibition
[19], and apart from a-synuclein, LB contain over 250 different
proteins from diverse cellular processes [71]. However, in this
context a-synuclein is not the downstream mediator of neurode-
generation because we show a-synuclein plays a redundant role in
the formation of inclusion bodies and neurodegeneration. This has
implications for all cases of LB in which there is no known
mutation of the a-synuclein gene. We emphasize that our data
does not exclude an important role for a-synuclein in PD and
events that initiate neurodegeneration, but provides evidence that
proteasomal dysfunction may be a relevant factor immediately
responsible for neuronal death, which may be amplified by, as well
as accompanied by, aggregation of a-synuclein.
Several in vitro studies, including primary cortical neurones,
modeling proteasomal dysfunction by applying pharmacological
inhibitors have shown 20S proteasome inhibition activates the
ALP [34,35]. Using similar methods to evaluate this pathway, we
did not observe activation of the ALP in 26S proteasome-depleted
mouse neurones in vivo. Our findings are consistent with a recent
elegant in vivo study that only found cross-talk between the UPS
and ALP in neurones with increased a-synuclein burden, i.e. in
human wild-type a-synuclein transgenic mice. In normal mice,
induction of the ALP was not observed following proteasome
inhibition [18]. There are intrinsic differences between in vitro and
in vivo experimental model systems as well as different species, but
our findings extend the limited in vivo knowledge between the UPS
and ALP degradative systems in SNpc and cortical neurones.
Although aggregation of undegraded proteins in inclusions may
be an obvious non-specific consequence of disrupted neuronal
homeostasis, the overt paranuclear accumulation of morpholog-
ically-impaired mitochondria in 26S proteasome-depleted neu-
rones is significant. Models of proteasomal dysfunction using
pharmacological 20S inhibitors have described neuronal death
and the formation of cytoplasmic inclusions containing proteins
that are present in LB, i.e. ubiquitin and a-synuclein, but not
shown accumulation of mitochondria [34,35]. The UPS has
emerged as an important mechanism by which mitochondrial
proteins can be degraded whilst preserving mitochondrial func-
tion. Key molecules that regulate mitochondrial membrane
dynamics are proteasome substrates, supporting a model of
perturbed fission/fusion following 26S proteasomal dysfunction
[22,25]. The accumulation of aberrant mitochondria in 26S
proteasome-depleted neurones is also redolent of Parkin-mediated
mitophagy, a process that was recently shown to be facilitated by
the UPS [25,72]. Significantly, one study functionally linked the
UPS and ALP for mitophagy by showing that 26S proteasome-
mediated degradation of outer mitochondrial membrane proteins
was essential for mitophagy [38]. In this context our findings are
important because 26S proteasomal dysfunction did not lead to
activation of the ALP. The mitochondria-containing inclusions in
26S proteasome-depleted neurones may reflect impaired mito-
phagy. Our study supports a role for the UPS in mitochondrial
homeostasis in mammalian neurones in vivo.
The molecular events regulating mitochondrial homoeostasis in
neurones, including why impairment of the UPS leads to
mitochondrial compromise and how this may signal for neuronal
death, require further characterization to understand their
relevance to neurodegeneration and diseases such as PD. We
suggest subtle disturbances in mitochondrial homeostasis through
impairment of critical cellular systems such as the UPS with aging
may lead to the accumulation of dysfunctional mitochondria and
neurodegeneration. Pale bodies contain numerous mitochondria
and it is essential to understand the reasons behind their presence
in paranuclear inclusions [13]. Interestingly, recent publications
suggest a-synuclein may also be directly involved in mitochondrial
homeostasis [26–28,73–76]. Therefore, mutations or multiplica-
tions of Snca may act, similarly to products of PD-related genes
linked to mitochondria and well-known environmental factors, as
well as proteasomal dysfunction, to negatively influence mito-
chondrial homeostasis and lead to neurodegeneration.
In summary, our data highlight the importance of considering
broader mechanistic models, which also have connections to a-
synuclein, in events leading to neurodegeneration. For example,
one hypothetical model that may explain our findings and connect
the elements implicated in PD is failure of mitochondrial
homeostasis, with degradative systems (UPS, aggresome, ALP,
mitophagy) downstream of several factors known to be involved in
maintaining mitochondrial function, including a-synuclein. Pro-
teasomal inhibition and downstream effects on mitochondrial
homeostasis may be a critical feature leading to neurodegeneration
worthy of further investigation.
Supporting Information
Figure S1 (A) Double immunofluorescent staining for cyto-
chrome C (mitochondria, green) and LC3 (autophagosomes, red)
of sections from control (Psmc1fl/fl;CaMKIIa-Wt) and 26S protea-
some-depleted (Psmc1fl/fl;CaMKIIa-Cre) mice. Enlarged views of the
boxed areas are shown (zoom). Scale bar, 10 mm. (B) LC3-
immunopositive inclusions were evident in some nigral (Psmc1fl/
fl;THWt;Snca+/+) and cortical (Psmc1fl/fl;CaMKIIa-Wt;Snca+/+) neu-
rones, irrespective of the presence or absence of a-synuclein (data
not shown). Scale bar, 10 mm.
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